Icariin ameliorates LPS-induced acute lung injury in mice via complement C5a-C5aR1 and TLR4 signaling pathways
Copyright © 2024 Elsevier B.V. All rights reserved..
Acute lung injury (ALI) is an acute respiratory-related progressive disorder, which lacks specific pharmacotherapy. Icariin (ICA) has been shown to be effective in treating ALI. However, the targets and pharmacological mechanisms underlying the effects of ICA in the treatment of ALI are relatively lacking. Based on network pharmacology and molecular docking analyses, the gene functions and potential target pathways of ICA in the treatment of ALI were determined. In addition, the underlying mechanisms of ICA were verified by immunohistochemistry, immunofluorescence, quantitative Real-time PCR, and Western blot in LPS-induced ALI mice. The biological processes targeted by ICA in the treatment of ALI included the pathological changes, inflammatory response, and cell signal transduction. Network pharmacology, molecular docking, and in vivo experimental results revealed that ICA inhibited the complement C5a-C5aR1 axis, TLR4 mediated NF-κB, MAPK, and JAK2-STAT3 signaling pathways related gene and protein expressions, and decreased inflammatory cytokine, chemokine, adhesion molecule expressions, and mitochondrial apoptosis in LPS-induced ALI.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
---|---|
Enthalten in: |
International immunopharmacology - 131(2024) vom: 20. Apr., Seite 111802 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Guo, Jing [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 10.04.2024 Date Revised 12.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.intimp.2024.111802 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369568109 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369568109 | ||
003 | DE-627 | ||
005 | 20240413232535.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240312s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.intimp.2024.111802 |2 doi | |
028 | 5 | 2 | |a pubmed24n1374.xml |
035 | |a (DE-627)NLM369568109 | ||
035 | |a (NLM)38467082 | ||
035 | |a (PII)S1567-5769(24)00320-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Guo, Jing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Icariin ameliorates LPS-induced acute lung injury in mice via complement C5a-C5aR1 and TLR4 signaling pathways |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.04.2024 | ||
500 | |a Date Revised 12.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
520 | |a Acute lung injury (ALI) is an acute respiratory-related progressive disorder, which lacks specific pharmacotherapy. Icariin (ICA) has been shown to be effective in treating ALI. However, the targets and pharmacological mechanisms underlying the effects of ICA in the treatment of ALI are relatively lacking. Based on network pharmacology and molecular docking analyses, the gene functions and potential target pathways of ICA in the treatment of ALI were determined. In addition, the underlying mechanisms of ICA were verified by immunohistochemistry, immunofluorescence, quantitative Real-time PCR, and Western blot in LPS-induced ALI mice. The biological processes targeted by ICA in the treatment of ALI included the pathological changes, inflammatory response, and cell signal transduction. Network pharmacology, molecular docking, and in vivo experimental results revealed that ICA inhibited the complement C5a-C5aR1 axis, TLR4 mediated NF-κB, MAPK, and JAK2-STAT3 signaling pathways related gene and protein expressions, and decreased inflammatory cytokine, chemokine, adhesion molecule expressions, and mitochondrial apoptosis in LPS-induced ALI | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Acute lung injury | |
650 | 4 | |a Complement | |
650 | 4 | |a Icariin | |
650 | 4 | |a Inflammation | |
650 | 4 | |a Mitochondrial apoptosis | |
650 | 7 | |a Complement C5a |2 NLM | |
650 | 7 | |a 80295-54-1 |2 NLM | |
650 | 7 | |a Flavonoids |2 NLM | |
650 | 7 | |a icariin |2 NLM | |
650 | 7 | |a VNM47R2QSQ |2 NLM | |
650 | 7 | |a Lipopolysaccharides |2 NLM | |
650 | 7 | |a NF-kappa B |2 NLM | |
650 | 7 | |a Toll-Like Receptor 4 |2 NLM | |
650 | 7 | |a Receptors, Complement |2 NLM | |
700 | 1 | |a Zhang, Qi-Yun |e verfasserin |4 aut | |
700 | 1 | |a Xu, Lin |e verfasserin |4 aut | |
700 | 1 | |a Li, Min |e verfasserin |4 aut | |
700 | 1 | |a Sun, Qian-Yun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 131(2024) vom: 20. Apr., Seite 111802 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
773 | 1 | 8 | |g volume:131 |g year:2024 |g day:20 |g month:04 |g pages:111802 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2024.111802 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 131 |j 2024 |b 20 |c 04 |h 111802 |